SurgVision
Private Company
Funding information not available
Overview
SurgVision is a clinical-stage medical device company focused on improving oncological surgery and interventions through advanced fluorescence imaging. Its core commercial asset is the EXPLORER AIR® II system, cleared by the US FDA for ICG-based perfusion imaging and for use with pafolacianine, alongside a CE mark in the EU. The company possesses a robust pipeline of imaging systems and targeted agents for open, minimally invasive, and interventional procedures, aiming to address the critical unmet need of incomplete tumor resection which occurs in up to 40% of surgeries.
Technology Platform
Proprietary high-sensitivity near-infrared (NIR) fluorescence imaging platform for real-time visualization of tumors during surgery and interventional procedures, designed for use with both non-targeted (e.g., ICG) and tumor-targeted fluorescent agents.
Opportunities
Risk Factors
Competitive Landscape
SurgVision competes in the fluorescence-guided surgery market against large medtech companies like Stryker (SPY-PHI), Karl Storz, Olympus, and Medtronic, as well as other specialists. Its differentiation is based on claims of superior sensitivity in its imaging systems and its development of targeted agents. Being part of Bracco provides a strategic advantage in distribution and credibility.